ABSTRACT
The delivery of pharmacologically active substances, such as synthetic drugs, natural compounds, gene material, and many other pharmaceutical products, has been widely studied and investigated over the last half century. In fact, scientists working in the ϐield of pharmacological active substances easily understood that the main problem of such molecules is represented by their wide and nonspeciϐic biodistribution once administered in the human body. This reϐlects, without any doubt, in an increase in toxicity and contemporaneously in both a decreased patient compliance and decreased beneϐit-risk ratio.
